Research progress of Dexamethasone intravitreal implants in the treatment of diabetic macular edema
10.3980/j.issn.1672-5123.2025.1.15
- VernacularTitle:地塞米松玻璃体内植入剂治疗糖尿病性黄斑水肿的研究进展
- Author:
Xiaoting YUAN
1
,
2
,
3
;
Jiao HUANG
1
,
2
,
3
;
Xiaojuan CHENG
1
,
2
,
3
;
Rong LI
1
,
2
,
3
;
Lishuai XU
1
,
2
,
3
Author Information
1. Medical School of Ophthalmology &
2. Optometry, North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
3. Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
- Publication Type:Journal Article
- Keywords:
Dexamethasone intravitreal implant;
diabetic macular edema;
inflammation;
combination therapy
- From:
International Eye Science
2025;25(1):82-87
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic macular edema(DME), a serious complication of diabetic retinopathy(DR), is a chronic condition caused by multiple factors. Throughout its progression, inflammatory factors and vascular endothelial growth factor(VEGF)play a critical role. Anti-VEGF drugs have shown significant effectiveness in the treatment of DME; however, some patients may experience persistent DME after injection or require frequent injections. Dexamethasone intravitreal implants(DEX implants)serve as a sustained-release implant characterized by a reasonable release profile and high bioavailability. They offer safe, effective, and prolonged anti-inflammatory effects, aiding in the repair of retinal barrier and reduction of exudation. To further enhance patients' visual quality, exploring the efficacy of DEX implants in combination with existing treatment regimens has great clinical significance. This review primarily discusses the research advancements in DEX implants, focusing on their pharmacological properties, indications for use, and their combination with existing drugs and treatment methods. It also evaluates the advantages and disadvantages of combination therapy or switching to DEX implants compared to current standard treatments, aiming to provide guidance for personalized treatment options for patients with DME.
